Cibus

CIBUS INC

Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.

Apple Inc.

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

AAPL

ATRC

CBUS

FLNC

NDSN

NFLX

SCHW

Apple To $183? Here Are 10 Top Analyst Forecasts For Wednesday

wall-street-ai15

Equities

Eurozone

Commodities

Intraday Update

AIOT

APLT

LUNR

WHLR

Dow Jumps Over 100 Points; Fed Cuts Interest Rates By 0.5%

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Crude Oil Moves Lower; PowerFleet Shares Spike Higher

Cibus Inc

Press Releases

General

Cibus' Agriculture Breeding Breakthroughs Create New Industry Paradigms for Development and Commercialization of Plant Traits

Financing

Cibus, Inc. Announces $22.6 Million Registered Direct Offering Priced Above Nasdaq's Minimum Price in Accordance with Nasdaq Rules

Cibus to Participate in the Sidoti Micro Cap Conference

Management

Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

Restaurants

Cibus Announces Important Update to Rice Gene Editing Conversion Rates

Cibus Announces Leadership Change and CEO Succession Plan

Health Care

Cibus' Achieves Another Milestone for a Durable White Mold (Sclerotinia) Resistance Trait in Canola

Cibus to Report Fourth Quarter 2024 Financial Results on March 20, 2025 After the Market Close and Host Conference Call

Cibus Welcomes the European Union's Progress as Legislation for New Genomic Techniques to Boost Innovation and Sustainability Moves Forward

Earnings

Cibus Reports Fourth Quarter Financial Results and Provides Business Update

CLLS

CLXT

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Adicet Bio

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Aligos Therapeutics

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Aerovate Therapeutics, Inc. - Common Stock

Aerovate Therapeutics

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Cue Biopharma

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

IGM Biosciences

I-MAB

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

Inozyme Pharma

IO Biotech

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

MediciNova

Mural Oncology

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

Pyxis Oncology

Skye Bioscience

Sutro Biopharma

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

Exagen

HC Wainwright & Co.

Canaccord Genuity

Alliance Global Partners

Comments

Cibus

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga